Citronberg Jessica, Kantor Elizabeth D, Potter John D, White Emily
1] Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA [2] Department of Epidemiology, University of Washington, Seattle, Washington, USA.
Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Am J Gastroenterol. 2014 Oct;109(10):1640-9. doi: 10.1038/ajg.2014.233. Epub 2014 Sep 16.
Constipation and laxative use have been hypothesized to increase colorectal cancer (CRC) risk, but existing epidemiologic studies have been inconclusive. To address this issue, the authors prospectively examined the association between CRC incidence and constipation, non-fiber laxative use, and fiber laxative use among 75,214 participants of the VITamins And Lifestyle study.
Information on bowel movement frequency as well as average 10-year non-fiber laxative use, fiber laxative use, and constipation was ascertained by means of a questionnaire. Patients were followed from the time of receipt of the baseline questionnaire (2000-2002) until 2008 for CRC incidence, over which time 558 incident CRC cases occurred. Cox proportional hazard models were used to estimate the multivariate-adjusted hazard ratios (HRs) and 95% confidence intervals (95% CI).
Compared with individuals who used non-fiber laxatives less than once per year, the HRs associated with low (1-4 times per year) and high (≥5 times per year) use were 1.49 (95% CI: 1.04-2.14) and 1.43 (95% CI: 0.82-2.28), respectively (Ptrend=0.05). HRs for CRC were statistically significantly decreased and lowest in individuals who reported using fiber laxatives often (4+ days per week for 4+ years) vs. those who reported no use (HR=0.44; 95% CI: 0.21-0.95), although the trend was not significant (Ptrend=0.19). No statistically significant associations between bowel movement frequency or constipation and CRC risk were observed.
Findings from this study suggest that risk for CRC increases with non-fiber laxative use and decreases with fiber laxative use. However, further observational and experimental studies are needed to clarify these relationships before drawing conclusions about the preferred treatment of constipation.
便秘和使用泻药被认为会增加结直肠癌(CRC)风险,但现有的流行病学研究尚无定论。为解决这一问题,作者对维生素与生活方式研究中的75214名参与者进行了前瞻性研究,以探讨结直肠癌发病率与便秘、非纤维类泻药使用及纤维类泻药使用之间的关联。
通过问卷调查确定排便频率以及10年期间非纤维类泻药、纤维类泻药的平均使用情况和便秘情况。从收到基线调查问卷(2000 - 2002年)开始对患者进行随访,直至2008年观察结直肠癌发病率,在此期间共发生558例结直肠癌病例。采用Cox比例风险模型估计多变量调整后的风险比(HRs)和95%置信区间(95%CI)。
与每年使用非纤维类泻药少于1次的个体相比,每年使用次数少(1 - 4次)和多(≥5次)的个体的HR分别为1.49(95%CI:1.04 - 2.14)和1.43(95%CI:0.82 - 2.28)(P趋势 = 0.05)。与未使用纤维类泻药的个体相比,经常使用纤维类泻药(每周4天以上,持续4年以上)的个体患结直肠癌的HR在统计学上显著降低且最低(HR = 0.44;95%CI:0.21 - 0.95),尽管趋势不显著(P趋势 = 0.19)。未观察到排便频率或便秘与结直肠癌风险之间存在统计学显著关联。
本研究结果表明,结直肠癌风险随非纤维类泻药使用增加而升高,随纤维类泻药使用而降低。然而,在就便秘的首选治疗方法得出结论之前,还需要进一步的观察性和实验性研究来阐明这些关系。